Known active infections
Patients with clinically significant active infections
Active clinically serious infections or other serious uncontrolled medical conditions
Uncontrolled infections
No active serious infections or other conditions precluding chemotherapy
Active or uncontrolled infections
Active or uncontrolled infections
Any evidence of serious active infections; any infections being treated must complete antibiotic therapy at least  days before planned first dose.
Uncontrolled active systemic infections
Active infections
Active or uncontrolled infections
Infections such as pneumonia or wound infections that would preclude protocol therapy.
Uncontrolled infections.
No uncontrolled infections;
No uncontrolled infections;
FOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious infections (> CTCAE grade )
No active infections
Active infections within  hours of study entry
Active uncontrolled acute infections
Evidence of active infections =<  days prior to initiation of study drug therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry)
Known active infections
CELL PROCUREMENT: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-respiratory syncytial virus (RSV), isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded
LYMPHODEPLETION: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-RSV, isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded
Active, clinically serious infections or other serious uncontrolled medical conditions
Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.
Uncontrolled infections
Active or uncontrolled infections
Active or uncontrolled infections
Not have active, uncontrolled infections
Active, uncontrolled infections
Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.
Active clinically serious infections (> CTCAE grade )
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least  weeks before study entry
Active known clinically serious infections
Evidence of active infections
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Evidence of active infections
Uncontrolled infections
Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.
Patients with active, uncontrolled infections
Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.
Active and uncontrolled infections
Patients with untreated or uncontrolled infections
No uncontrolled infections as determined by the investigator
Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
Recent or ongoing serious infections within  weeks
Evidence of active infections
Patients with serious uncontrolled infections will not be eligible
Patients with serious uncontrolled infections at the time of planned transplant will be excluded
Known infections:
Has uncontrolled active infection of any kind. (Patients with infections controlled by active antibiotic treatment are eligible).
Active and uncontrolled systemic infections.
Active clinically serious infections (? CTCAE v. Grade ).
Active infections
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least  weeks before study entry
DONOR: Current serious systemic illness including uncontrolled infections
Current uncontrolled infections.
Active clinically serious infections or other serious uncontrolled medical conditions
Uncontrolled infections
Patients with serious uncontrolled infections at the time of transplant will be excluded
Active or uncontrolled infections
Poor medical risk because of systemic diseases (e.g. active uncontrolled infections) in addition to the qualifying disease under study.
Active, unresolved infections
Severe infections at the time of randomization
Active uncontrolled infections
Active clinically serious infections (> grade )
Active clinically serious infections > CTCAE Grade 
Infections such as pneumonia or wound infections that would preclude protocol therapy
Active clinically serious infections
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least  weeks before study entry
Any evidence of serious active infections
Concurrent serious uncontrolled infections requiring treatment or known infection with HIV
Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.
Uncontrolled infections
Patients must not have any active infections
Patients with severe systemic infections
Uncontrolled systemic disease like active infections
Patients with active clinical infections
Known active infections
c. Active or failed to control serious infections (CTCAE version . > grade  infections)
Known active infections
DONOR: Current serious systemic illness including uncontrolled infections
Any evidence of serious active infections.
DONOR: No active or chronic infections
Clinically significant uncontrolled illness or active infections
Active or uncontrolled infections
. Any evidence of serious active infections.
Patients with active infections, including HIV, will be excluded
Any evidence of serious active infections
Infections
Active clinically serious infections of > Grade  and/or active infections that require treatment with systemic agent
Severe systemic diseases or active uncontrolled infections
Recent infections not meeting the criteria for severe infections within  weeks prior to Cycle , Day 
Participants who have active, uncontrolled infections.
Uncontrolled (not being treated) infections at the time of cytoreduction
Severe infections within  weeks prior to Day 
Active clinically serious infections of > Grade 
Patients must have no evidence of active infections at the time of transplantation
Patient with active infections
Active and uncontrolled infections
Patients with uncontrolled infections
Patients with ongoing symptomatic dental infections
active infections of the oral cavity
Active infection (except mild upper respiratory infections)
Patients with clinically significant active infections
Patients with active urinary tract infections
Patients should not have active infections or concurrent neoplastic disease except for skin cancer
Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease.
Active infections of oral cavity
Patients with active infections.
Active, uncontrolled infections within  days of study entry requiring systemic therapy.
